Le Lézard3h
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Responder analyses demonstrated that approximately nine out of 10 patients treated with BIMZELX who achieved PASI90 at Year 1, and over seven out of 10 patients who achieved complete skin clearance ...
Psoriatic Arthritis Pipeline Insight Report 2024: Emerging Therapies and Key Pharma Players Involved
The "Psoriatic Arthritis - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A notable advancement has been made within the Psoriatic Arthritis (PsA) therapeutic area, ...
Dr. Mahesh Tumdam - Arthritis And Morning Stiffness
In contrast, inflammatory arthritis types, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, cause morning stiffness due to overnight accumulation of inflammation in the ...
Daily22h
FOREMOST Trial Reveals Apremilast Enhances Disease Control in Early Oligoarticular Psoriatic Arthritis
USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...
Monthly Prescribing Reference22h
Bimzelx Approval Expanded to Include 3 Types of Inflammatory Arthritis
The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...